612 related articles for article (PubMed ID: 12854088)
41. Treatment of Aspergillus terreus infections: a clinical problem not yet resolved.
Pastor FJ; Guarro J
Int J Antimicrob Agents; 2014 Oct; 44(4):281-9. PubMed ID: 25190543
[TBL] [Abstract][Full Text] [Related]
42. Combination therapy with terbinafine and amphotericin B in a rabbit model of experimental invasive aspergillosis.
Kirkpatrick WR; Vallor AC; McAtee RK; Ryder NS; Fothergill AW; Rinaldi MG; Patterson TF
Antimicrob Agents Chemother; 2005 Nov; 49(11):4751-3. PubMed ID: 16251321
[TBL] [Abstract][Full Text] [Related]
43. [Guideline based treatment of invasive aspergillosis].
Karthaus M
Mycoses; 2010 May; 53 Suppl 1():36-43. PubMed ID: 20433655
[TBL] [Abstract][Full Text] [Related]
44. Efficacy of caspofungin against Aspergillus terreus.
Barchiesi F; Spreghini E; Santinelli A; Fothergill AW; Fallani S; Manso E; Pisa E; Giannini D; Novelli A; Cassetta MI; Mazzei T; Rinaldi MG; Scalise G
Antimicrob Agents Chemother; 2005 Dec; 49(12):5133-5. PubMed ID: 16304185
[TBL] [Abstract][Full Text] [Related]
45. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia.
Petraitiene R; Petraitis V; Groll AH; Sein T; Schaufele RL; Francesconi A; Bacher J; Avila NA; Walsh TJ
Antimicrob Agents Chemother; 2002 Jan; 46(1):12-23. PubMed ID: 11751105
[TBL] [Abstract][Full Text] [Related]
46. Meta-analysis of nebulized amphotericin B to prevent or treat pulmonary aspergillosis in immunosuppressed animals.
Ho KM; Duff O; Chambers D; Murray R
Transpl Infect Dis; 2008 Jun; 10(3):168-76. PubMed ID: 18194368
[TBL] [Abstract][Full Text] [Related]
47. Experimental murine aspergillosis. Comparison of amphotericin B and a new polyene antifungal drug, SCH 28191.
Graybill JR; Kaster SR
Am Rev Respir Dis; 1984 Feb; 129(2):292-5. PubMed ID: 6364905
[TBL] [Abstract][Full Text] [Related]
48. Posaconazole enhances the activity of amphotericin B against Aspergillus hyphae in vitro.
Perkhofer S; Lugger H; Dierich MP; Lass-Flörl C
Antimicrob Agents Chemother; 2007 Feb; 51(2):791-3. PubMed ID: 17116665
[TBL] [Abstract][Full Text] [Related]
49. Amphotericin B in vitro resistance is associated with fatal Aspergillus flavus infection.
Hadrich I; Makni F; Neji S; Cheikhrouhou F; Bellaaj H; Elloumi M; Ayadi A; Ranque S
Med Mycol; 2012 Nov; 50(8):829-34. PubMed ID: 22587728
[TBL] [Abstract][Full Text] [Related]
50. A novel cause of invasive pulmonary infection in an immunocompetent patient: Aspergillus candidus.
Ribeiro SC; Santana AN; Arriagada GH; Martins JE; Takagaki TY
J Infect; 2005 Nov; 51(4):e195-7. PubMed ID: 16291268
[TBL] [Abstract][Full Text] [Related]
51. In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis.
Lass-Flörl C; Kofler G; Kropshofer G; Hermans J; Kreczy A; Dierich MP; Niederwieser D
J Antimicrob Chemother; 1998 Oct; 42(4):497-502. PubMed ID: 9818749
[TBL] [Abstract][Full Text] [Related]
52. Dectin-1-Targeted Antifungal Liposomes Exhibit Enhanced Efficacy.
Ambati S; Ferarro AR; Kang SE; Lin J; Lin X; Momany M; Lewis ZA; Meagher RB
mSphere; 2019 Feb; 4(1):. PubMed ID: 30760610
[No Abstract] [Full Text] [Related]
53. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America.
Stevens DA; Kan VL; Judson MA; Morrison VA; Dummer S; Denning DW; Bennett JE; Walsh TJ; Patterson TF; Pankey GA
Clin Infect Dis; 2000 Apr; 30(4):696-709. PubMed ID: 10770732
[TBL] [Abstract][Full Text] [Related]
54. Aspergillus susceptibility testing in patients with cancer and invasive aspergillosis: difficulties in establishing correlation between in vitro susceptibility data and the outcome of initial amphotericin B therapy.
Lionakis MS; Lewis RE; Chamilos G; Kontoyiannis DP
Pharmacotherapy; 2005 Sep; 25(9):1174-80. PubMed ID: 16164392
[TBL] [Abstract][Full Text] [Related]
55. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole.
Sutton DA; Sanche SE; Revankar SG; Fothergill AW; Rinaldi MG
J Clin Microbiol; 1999 Jul; 37(7):2343-5. PubMed ID: 10364610
[TBL] [Abstract][Full Text] [Related]
56. Virulence and thrombocyte affectation of two Aspergillus terreus isolates differing in amphotericin B susceptibility.
Speth C; Blum G; Hagleitner M; Hörtnagl C; Pfaller K; Posch B; Ott HW; Würzner R; Lass-Flörl C; Rambach G
Med Microbiol Immunol; 2013 Oct; 202(5):379-89. PubMed ID: 23722593
[TBL] [Abstract][Full Text] [Related]
57. Trends in the Prevalence of Amphotericin B-Resistance (AmBR) among Clinical Isolates of Aspergillus Species.
Fakhim H; Badali H; Dannaoui E; Nasirian M; Jahangiri F; Raei M; Vaseghi N; Ahmadikia K; Vaezi A
J Mycol Med; 2022 Nov; 32(4):101310. PubMed ID: 35907396
[TBL] [Abstract][Full Text] [Related]
58. Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis.
Wiederhold NP; Tam VH; Chi J; Prince RA; Kontoyiannis DP; Lewis RE
Antimicrob Agents Chemother; 2006 Feb; 50(2):469-73. PubMed ID: 16436698
[TBL] [Abstract][Full Text] [Related]
59. In-vitro and in-vivo susceptibility of Aspergillus fumigatus to a novel conjugated styryl ketone.
Manavathu EK; Dimmock JR; Vashishtha SC; Cutright J; Chandrasekar PH
J Antimicrob Chemother; 1998 Nov; 42(5):585-90. PubMed ID: 9848441
[TBL] [Abstract][Full Text] [Related]
60. Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma.
Chen J; Li H; Li R; Bu D; Wan Z
J Antimicrob Chemother; 2005 Jan; 55(1):31-7. PubMed ID: 15563516
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
